Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB
Open accessThe DOI matches its Crossref record; 265 of the 268 references it cites were found in a registry or an index.
Abstract
The blood–brain barrier (BBB) plays a vital role in the protection and maintenance of homeostasis in the brain. In this way, it is an interesting target as an interface for various types of drug delivery, specifically in the context of the treatment of several neuropathological conditions where the therapeutic agents cannot cross the BBB. Drug toxicity and on-target specificity are among some of the limitations associated with current neurotherapeutics. In recent years, advances in nanodrug delivery have enabled the carrier system containing the active therapeutic drug to target the signaling pathways and pathophysiology that are closely linked to central nervous system (CNS) disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), multiple sclerosis (MS), brain tumor, epilepsy, ischemic stroke, and neurodegeneration. At present, among the nano formulations, solid lipid nanoparticles (SLNs) have emerged as a putative drug carrier system that can deliver the active therapeutics (drug-loaded SLNs) across the BBB at the target site of the brain, offering a novel approach with controlled drug delivery, longer circulation time, target specificity, and higher efficacy, and more importantly, reducing toxicity in a biomimetic way. This paper highlights the synthesis and application of SLNs as a novel nontoxic formulation strategy to carry CNS drugs across the BBB to improve the use of therapeutics agents in treating major neurological disorders in future clinics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, SLNs utilize receptor-mediated and adsorptive-mediated transcytosis to cross the BBB and enable sustained drug release [74].”
From Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review (2026) · cites this paper as [74]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“SLNs can effectively transport drugs across the BBB, enabling the delivery of compounds that are otherwise impermeable [74].”
From Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review (2026) · cites this paper as [74]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–265 of 265
Influence of the Formulation for Solid Lipid Nanoparticles Prepared with a Membrane Contactor
Ahmed El-Harati, A., Charcosset, C., & Fessi, H. (2006) · Pharmaceutical Development and Technology · doi:10.1080/10837450600561182 · Cited by 70
Samia, O., Hanan, R., & Kamal, E. T. (2012) · Drug Delivery · doi:10.3109/10717544.2011.644349 · Cited by 68 · cited 1×
“Recent research findings have shown promising results for SLNs loaded with carbamazepine with better anticonvulsant effect than nanoemulged-loaded carba-mazepine [209].”
A novel approach based on lipid nanoparticles (SLN®) for topical delivery of α-lipoic acid
Souto, E. B., Müller, R. H., & Gohla, S. (2005) · Journal of Microencapsulation · doi:10.1080/02652040500162378 · Cited by 67
Passerini, N., Qi, S., Albertini, B., Grassi, M., Rodriguez, L., & Craig, D. Q. M. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21854 · Cited by 67
Effect of P‐glycoprotein modulators on the pharmacokinetics of camptothecin using microdialysis
Tsai, T., Lee, C. H., & Yeh, P.-H. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704363 · Cited by 67 · cited 1×
“For example, the anticancer drug camptothecin can cross the BBB and be used in glioblastoma therapy [71,72], although it cannot be used in clinical protocols due to its poor stability.”
Advances in strategies to improve drug delivery to brain tumors
Newton, H. B. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.10.1495 · Cited by 67 · cited 1×
“The main BBB components are endothelial cells, astrocytic end-feet links, basal lamina, tight junctions, and pericytes [10–12] (Figure 1).”
Holden, C. A., Yuan, Q., Yeudall, W. A., Lebman, D. A., & Yang, H. (2010) · PubMed Central · Cited by 67
Blood-Brain Barrier Disruption in the Treatment of Brain Tumors
Blanchette, M., & Fortin, D. (2011) · Methods in Molecular Biology · doi:10.1007/978-1-60761-938-3_23 · Cited by 64 · cited 1×
“Moreover, there are several approaches developed to increase the permeability of the BBB such as injection of hyperosmolar mannitol [32] causing reversible disruption, or by providing ultrasound as physical stimulus [33,34].”
Catanionic solid lipid nanoparticles carrying doxorubicin for inhibiting the growth of U87MG cells
Kuo, Y., & Liang, C.-T. (2011) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2011.02.011 · Cited by 64
Solid lipid nanoparticles as delivery systems for Gambogenic acid
Huang, X., Chen, Y., Peng, D., Li, Q., Wang, X., Wang, D., & Chen, W. (2012) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2012.08.058 · Cited by 64
Talluri, S. V., Pindiprolu, S. K. S. S., Chintamaneni, P. K., Tummala, S., & Kumar, S. N. (2017) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2017.1313267 · Cited by 64 · cited 1×
“Other studies are based on how to attaching a targeting ligand to an SLN, such as by linking a fatty acid of the NP to an amino group of the ligand [113], an amino group of a phospholipid to an acid group of the ligand [114], or an amino group of the chitosan coating to an acid group of the ligand…”
Techniques for the Preparation of Solid Lipid Nano and Microparticles
Battaglia, L., Gallarate, M., Panciani, P. P., Ugazio, E., Sapino, S., Peira, E., & Chirio, D. (2014) · InTech eBooks · doi:10.5772/58405 · Cited by 61 · cited 1×
“The main component precursors required for SLN synthesis are emulsions, microemulsions, and micellar solutions [119], which include solid lipid (beeswax, stearic acid, cholesterol, caprylic/capric triglyceride, cetylpalmitate, glyceryl stearate (-mono, and -tri), glyc-eryl trilaurate, glyceryl…”
Alzheimer, dementia and the living will: a proposal
Burlá, C., Rego, G., & Nunes, R. (2014) · Medicine, Health Care and Philosophy · doi:10.1007/s11019-014-9559-8 · Cited by 56 · cited 1×
“It is characterized by frequent cognitive function loss such as loss of memory and frequent behavioral change, leading to death [218].”
New Methods for Lipid Nanoparticles Preparation
Corrias, F., & Lai, F. (2011) · Recent Patents on Drug Delivery & Formulation · doi:10.2174/187221111797200597 · Cited by 56
Tran, T. H., Ramasamy, T., Cho, H. J., Kim, Y. I., Poudel, B. K., Choi, H., Yong, C. S., & Kim, J. O. (2014) · Journal of Nanoscience and Nanotechnology · doi:10.1166/jnn.2014.8722 · Cited by 56
Biomaterials to Neuroprotect the Stroke Brain: A Large Opportunity for Narrow Time Windows
González‐Nieto, D., Fernández-Serra, R., Pérez‐Rigueiro, J., Panetsos, F., Martínez‐Murillo, R., & Guinea, G. V. (2020) · Cells · doi:10.3390/cells9051074 · Cited by 56
Electrospray technique for solid lipid-based particle production
Trotta, M., Cavalli, R., Trotta, C., Bussano, R., & Costa, L. (2010) · Drug Development and Industrial Pharmacy · doi:10.3109/03639040903241817 · Cited by 55
Bodmeier, R. A., Wang, J., & Bhagwatwar, H. (1992) · Journal of Microencapsulation · doi:10.3109/02652049209021226 · Cited by 54
Self-citationKuo, Y.-C., & Wang, I.-H. (2016) · Journal of Drug Targeting · doi:10.3109/1061186x.2015.1132223 · Cited by 52 · cited 1×
“This could be attributed to the ability of these drug-loaded SLNs to infiltrate the BBB, suggesting their potential therapeutic use in future clinics for the treat-ment of multiple forms glioblastoma [245–249].”
Ibuprofen and Lipoic Acid Diamides as Potential Codrugs with Neuroprotective Activity
Sozio, P., D'Aurizio, E., Iannitelli, A., Cataldi, A., Zara, S., Cantalamessa, F., Nasuti, C., & Di Stefano, A. (2010) · Archiv der Pharmazie · doi:10.1002/ardp.200900152 · Cited by 51 · cited 2×
“Glutathione (GSH), lipoic acid (LA), carnosine, and caffeic acid provide potent antioxidant assistance in counteracting the free radicals produced by the ROS [222,271].”
Lipid microparticles as sustained release system for a GnRH antagonist (Antide)
Curto, M. D. D., Chicco, D., D’Antonio, M., Ciolli, V., Dannan, H., Durso, S., Neuteboom, B., Pompili, S., Schiesaro, S., & Esposito, P. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00120-2 · Cited by 51
Macrophages and liposomes in inflammatory disease: Friends or foes?
Crielaard, B. J., Lammers, T., Morgan, M. E., Chaabane, L., Carboni, S., Greco, B. M., Zaratin, P., Kraneveld, A. D., & Storm, G. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.12.045 · Cited by 49 · cited 1×
“Some primary study findings revealed that SLNs loaded with vincristine and temozolomide, synthesized by the high-shear homogenization technique, have a profound, sustained release, suggesting future clinical use as a controlled delivery system [265].”
Delivery of peptides and proteins through the blood-brain barrier
Bickel, U., Yoshikawa, T., & Pardridge, W. M. (1993) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(93)90048-9 · Cited by 49
Novel delivery systems fro drug targeting to the brain
Reddy, J. S., & Venkateswarlu, V. (2004) · Drugs of the Future · doi:10.1358/dof.2004.029.01.872585 · Cited by 48 · cited 1×
“SLNs can encapsulate both hydrophilic and lipophilic drugs [41,57,58].”
Stroke Management: An Emerging Role of Nanotechnology
Sarmah, D., Saraf, J., Kaur, H., Pravalika, K., Tekade, R., Borah, A., Kalia, K., Dave, K., & Bhattacharya, P. (2017) · Micromachines · doi:10.3390/mi8090262 · Cited by 48 · cited 1×
“An advanced nanodrug delivery approach may contribute a novel treatment strategy to overcome the major hurdles during drug targeting for stroke management [264].”
Preparation of solid lipid nanoparticles in co-flowing microchannels
Zhang, S.-H., Shen, S., Chen, Z., Yun, J., Yao, K., Chen, B., & Chen, J. (2008) · Chemical Engineering Journal · doi:10.1016/j.cej.2008.07.024 · Cited by 46
Cacciatore, I., Baldassarre, L., Fornasari, E., Cornacchia, C., Stefano, A. D., Sozio, P., Cerasa, L. S., Fontana, A., Fulle, S., Filippo, E. S. D., et al. (2012) · ChemMedChem · doi:10.1002/cmdc.201200320 · Cited by 46 · cited 1×
“SLNs, as an advanced drug delivery approach, have been used to load the existing drugs, further improving bioavailability and therapeutic efficacy in treating AD [221,222].”
Leyva‐Gómez, G., González-Trujano, M. E., López-Ruiz, E., Couraud, P., Wekslerg, B., Romero, I. A., Miller, F., Delié, F., Allémann, É., & Quintanar‐Guerrero, D. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24044 · Cited by 46
Brain drug delivery by adsorption-mediated transcytosis
Zhu, X., Jin, K., Huang, Y., & Pang, Z. (2019) · Brain Targeted Drug Delivery System · doi:10.1016/b978-0-12-814001-7.00007-x · Cited by 46
Carlotti, M. E., Sapino, S., Trotta, M., Battaglia, L., Vione, D. V., & Pelizzetti, E. (2005) · Journal of Dispersion Science and Technology · doi:10.1081/dis-200045403 · Cited by 45
Kuo, Y., & Lee, C. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24388 · Cited by 41
Cingolani, G. M., Stefano, A. D., Mosciatti, B., Napolitani, F., Giorgioni, G., Ricciutelli, M., & Claudi, F. (2000) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00249-3 · Cited by 38 · cited 1×
“However, the required drug bioavailability is unsatisfactory [232,233], with lower therapeutic efficacy.”
Minelli, A., Conte, C., Cacciatore, I., Cornacchia, C., & Pinnen, F. (2012) · Amino Acids · doi:10.1007/s00726-011-1210-x · Cited by 38
Brain targeted solid lipid nanoparticles for brain ischemia: preparation andin vitrocharacterization
Morsi, N. M., Ghorab, D. M., & Badie, H. A. (2013) · Pharmaceutical Development and Technology · doi:10.3109/10837450.2012.734513 · Cited by 35 · cited 1×
“Vinpocetine loaded in a specialized SLN formulation may overcome the short-comings, such as a lower bioavailability and short half-life associated with free vinpocetine in the treatment of chronic cerebral vascular ischemia [215].”
Jabir, N., Tabrez, S., Firoz, C. K., Zaidi, S., Baeesa, S., Gan, S., Shakil, S., & Kamal, M. (2015) · Current Drug Metabolism · doi:10.2174/1389200215666141125142605 · Cited by 35
Parkinson's disease (PD) in the elderly: An example of geriatric syndrome (GS)?
Lauretani, F., Maggio, M. G., Silvestrini, C., Nardelli, A., Saccavini, M., & Ceda, G. P. (2011) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2011.03.002 · Cited by 34 · cited 1×
“Central nervous system (CNS) diseases are most commonly characterized by an imbalance in neurological function, leading to neuronal death [2–4].”
Bodmeier, R. A., Wang, J., & Bhagwatwar, H. (1992) · Journal of Microencapsulation · doi:10.3109/02652049209021227 · Cited by 34
Self-citationNew L‐Dopa Codrugs as Potential Antiparkinson Agents
Sozio, P., Iannitelli, A., Cerasa, L. S., Cacciatore, I., Cornacchia, C., Giorgioni, G., Ricciutelli, M., Nasuti, C., Cantalamessa, F., & Stefano, A. D. (2008) · Archiv der Pharmazie · doi:10.1002/ardp.200700228 · Cited by 33
Gaur, P. K., Mishra, S., Verma, A. K., & Verma, N. K. (2015) · Journal of Experimental Nanoscience · doi:10.1080/17458080.2015.1025301 · Cited by 33 · cited 1×
“The specialized SLN can overcome the poor absorption, instability at physiological pH, rapid metabolism, and systemic elimination of drugs [216,224–226], improving the AD treatment strategy.”
Re, F., Antonina, O., Sesana, Rivolta, I., Panariti, Brambilla, Nicolas, J., Couvreur, Andrieux, K., Masserini, et al. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s40297 · Cited by 33 · cited 1×
“In vivo [194] SLN carrying phosphatidic acid or cardiolipin High affinity for the A β peptide In vitro [195] Ferulic acid loaded SLN Overcome permeability issues and reduce oxidative stress in A β -treated cells In vitro [196] Epigallocatechin3-gallate”
Wang, J., Zhu, R., Sun, D., Sun, X., Geng, Z., Liu, H., & Wang, S. (2014) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2015.1925 · Cited by 33 · cited 1×
“The specialized SLN can overcome the poor absorption, instability at physiological pH, rapid metabolism, and systemic elimination of drugs [216,224–226], improving the AD treatment strategy.”
Self-citationChen, Y., Jin, R.-X., Zhou, Y., Zeng, J., Zhang, H., & Feng, Q.-R. (2006) · PubMed · Cited by 32
Amphotericin B loaded SLN prepared with the coacervation technique
BIANCO, M. A., Gallarate, M., Trotta, M., & Battaglia, L. (2010) · Journal of Drug Delivery Science and Technology · doi:10.1016/s1773-2247(10)50028-5 · Cited by 32
Production of lipid microparticles containing bioactive molecules functionalized with PEG
Vezzù, K., Borin, D., Bertucco, A., Bersani, S., Salmaso, S., & Caliceti, P. (2010) · The Journal of Supercritical Fluids · doi:10.1016/j.supflu.2010.05.013 · Cited by 30
Synthesis and activity of novel glutathione analogues containing an urethane backbone linkage
Cacciatore, I., Caccuri, A. M., Stefano, A. D., Luisi, G., Nalli, M., Pinnen, F., Ricci, G., & Sozio, P. (2003) · Il Farmaco · doi:10.1016/s0014-827x(03)00135-6 · Cited by 30 · cited 1×
“Glutathione (GSH), lipoic acid (LA), carnosine, and caffeic acid provide potent antioxidant assistance in counteracting the free radicals produced by the ROS [222,271].”
Sjöström, B., & Bergenståhl, B. (1992) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(92)90051-3 · Cited by 26
Bussano, R., Chirio, D., Costa, L., Turci, F., & Trotta, M. (2011) · Journal of Dispersion Science and Technology · doi:10.1080/01932691.2010.505876 · Cited by 25
Effectiveness of Muscimol‐containing Microparticles against Pilocarpine‐induced Focal Seizures
Kohane, D. S., Holmes, G. L., Chau, Y., Zurakowski, D., Langer, R., & Cha, B. H. (2002) · Epilepsia · doi:10.1046/j.1528-1157.2002.11202.x · Cited by 25 · cited 1×
“Similarly, muscimol SLNs [256] and amiloride loaded SLNs [257] were evidenced to have anticonvulsant effects, suppressing focal seizures in in vivo rat models with a better and more sustained release in comparison to the administration of free drugs only.”
Ali, A., KOLAPPAPILLAI, K., JALEESAHMAD, F., Dua, Y., IQBALKHAN, Z., & Vohora, D. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.05.003 · Cited by 25 · cited 1×
“Similarly, muscimol SLNs [256] and amiloride loaded SLNs [257] were evidenced to have anticonvulsant effects, suppressing focal seizures in in vivo rat models with a better and more sustained release in comparison to the administration of free drugs only.”
Minelli, A., Conte, C., Prudenzi, E., Cacciatore, I., Cornacchia, C., Taha, E., & Pinnen, F. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.03.011 · Cited by 21 · cited 1×
“Levodopa is the best drug of choice for PD to date [229–231], targeting the dopaminergic receptor.”
Djuzenova, C. S., Güttler, T., Berger, S., Katzer, A., & Flentje, M. P. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.3.5363 · Cited by 20 · cited 1×
“For example, the anticancer drug camptothecin can cross the BBB and be used in glioblastoma therapy [71,72], although it cannot be used in clinical protocols due to its poor stability.”
María, A., Barbassa, L., & de Melo, L. D. (2011) · InTech eBooks · doi:10.5772/14400 · Cited by 20
Receptor-mediated transportation through BBB
Zhang, Z., & Zhan, C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814001-7.00005-6 · Cited by 18 · cited 2×
“For example, organic cation and anion transporters, GLUT-1, and large neutral amino acid transporters (LAT), play an important role in the delivery of various biomolecules [84,86,87] and their substrates in a size- and stereo-selective manner [88].”
Mistraletti, G., Paroni, R. C., Umbrello, M., Salihovic, B. M., Coppola, S., Froio, S., Finati, E., Gasco, P., Savoca, A., Manca, D., et al. (2019) · Clinical Endocrinology · doi:10.1111/cen.13993 · Cited by 16 · cited 1×
“However, the clinical study showed that [278], in comparison to only melatonin, administration of SLN loaded with melatonin was adequate to obtain better pharmacological levels even in the early phase of critical illness, with a favorable pharmacokinetic profile.”
Powdered Lipid Nano and Microparticles: Production and Applications
Berton, A., Piel, G., & Évrard, B. (2011) · Recent Patents on Drug Delivery & Formulation · doi:10.2174/187221111797200588 · Cited by 13
How have advances in genetic technology modified movement disorder nosology?
Sturchio, A., Marsili, L., Mahajan, A., Grimberg, M. B., Kauffman, M., & Espay, A. J. (2020) · European Journal of Neurology · doi:10.1111/ene.14294 · Cited by 13 · cited 1×
“…the symptoms of HD, such as: FDA-approved tetra-benazine (Xenazine); deutetrabenazine (Austedo), haloperidol, risperidone (Risperdal), olanzapine (Zyprexa), quetiapine (Seroquel), amantadine (Gocovri ER, Osmolex ER), lev-etiracetam (Keppra, Elepsia XR, Spritam), and clonazepam (Klonopin) [235,236].”
A MODERN REVIEW ON SOLID LIPID NANOPARTICLES AS NOVEL CONTROLLED DRUG DELIVERY SYSTEM
Reddy, A., Parthiban, S., Vikneswari, A., & Senthilkumar, G. P. (2014) · Cited by 10
SLN BRAIN TARGETING DRUG DELIVERY FOR CNS: A NOVEL APPROACH
Mori, N. M., Sheth, N. R., Mendapara, V. P., Ashara, K. C., & Paun, J. S. (2014) · International Research Journal of Pharmacy · doi:10.7897/2230-8407.0509134 · Cited by 8
Sguizzato, M., Esposito, E., Drechsler, M., Gallerani, E., Gavioli, R., Mariani, P., Carducci, F., Cortesi, R., & Bergamini, P. (2017) · Journal of Chemistry · doi:10.1155/2017/3206298 · Cited by 6 · cited 1×
“This method is further restricted to lipids with a melting point above 70 ◦ C [183,184].”
Preparation and entrapment efficiency determination of solid lipid nanoparticles loaded levodopa
Shuiming, Z., Hou, D., Ping, Q. N., & Xu, Y. L. (2010) · Chinese Journal of Hospital Pharmacy · Cited by 3
Microemulsions as Precursors to Solid Nanoparticles
Mumper, R. J., & Jay, M. (2006) · UKnowledge (University of Kentucky) · Cited by 3
Misra, S., Kuhad, A., Kaur, I., & Chopra, K. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.05.544 · Cited by 2 · cited 1×
“In vivo study [191] Galantamine loaded SLN Enhanced bioavailability and improved drug delivery In vitro [192] Quercetin-loaded SLN Reverse neurodegeneration In vivo [193] Piperine loaded SLN”
Consenso Mexicano sobre el diagnóstico de la enfermedad de Huntington
Neri-Nani, G. A., López‐Ruiz, M., Estrada-Bellmann, I. E., Carrasco, H., Enríquez-Coronel, G., González-Usigli, H., Leal-Ortega, R., Otero-Cerdeira, E., Rodríguez-Alejandro, R., Aguilar, P., et al. (2016) · Archivos de Neurociencias · doi:10.31157/archneurosciencesmex.v21i1.112 · Cited by 2
Process for the production of nano-particles
Bertucco, A., CALICETI, P., & Elvassore, N. (2005) · Padua Research Archive (University of Padova) · Cited by 2
The effect of a pain management program in reducing the pain in patients with multiple sclerosis
Manee, F. M., Ahi, G., Ramazani, F., & Behnejad, S. (2016) · Journal of Research and Health · doi:10.7508/jrh.2016.03.007 · Cited by 1 · cited 1×
“Therefore, the failure of signal transmission in the brain results in a range of devastating physical, mental, and psychiatric problems [238–240].”
Research works printed but not linked: 7
- Dingler, A. (1998). Feste Lipid-Nanopartikel als Kolloidale Wirkstoffträgersysteme zur Dermalen Applikation. [Ph.D. Thesis, Freie Universität Berlin].
- Mehnert, 1998, Drug release and release mechanism of prednisolone loaded solid lipid nanoparticles, Pharmazie, 53, 552
- zur Muhlen, A. (1996). Feste Lipid Nanopartikel mit Prolongierter Wirkstoffliberation: Herstellung, Langzeitstabilität, Charakterisierung, Freisetzungsverhalten und Mechanismen. [Ph.D. Thesis, Free University of Berlin].
- Meyer, 1988, Wettkampf und Spiel in den Miniaturen der Manessischen Liederhandschrift, Stadion, 14, 1
- Nelluri, 2015, Formulation and evaluation of galantamine nanoparticles for neurological disorders, Int. J. Pharm. Chem. Biol. Sci., 5, 63
- Özdemir, Y.G., Pehlivan, S.B., and Sekerdag, E. (2017). Nanotechnology Methods for Neurological Diseases and Brain Tumors: Drug Delivery Across the Blood–Brain Barrier, Academic Press.
- Duarte, A.M.G. (2015). Resveratrol and Grape’s Extract-Loaded Solid Lipid Nanoparticles for the Treatment of Parkinson’s and Alzheimer’s Diseases. [Master’s Thesis, Faculty of Engineering of University of Porto].
Cited by
Huang, Y., Guo, X., Wu, Y., Chen, X., Feng, L., Xie, N., & Shen, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01745-z · Cited by 490
Recent Progress in Nanostructured Smart Drug Delivery Systems for Cancer Therapy: A Review
Khan, M. I., Hossain, M. I., Hossain, M. K., Rubel, M. H. K., Hossain, K. M., Mahfuz, A. M. U. B., & Anik, M. I. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.2c00002 · Cited by 370
Review on the Scale-Up Methods for the Preparation of Solid Lipid Nanoparticles
Khairnar, S. V., Pagare, P., Thakre, A., Nambiar, A. R., Junnuthula, V., Abraham, M. C., Kolimi, P., Nyavanandi, D., & Dyawanapelly, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091886 · Cited by 263
“The spray-drying technique procedure is reproduced from [43].”
MethodAkombaetwa, N., Ilangala, A. B., Thom, L., Memvanga, P. B., Witika, B. A., & Buya, A. B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020656 · Cited by 215
Correia, A. C., Monteiro, A. R., Silva, R., Moreira, J. N., Sousa Lobo, J. M., & Silva, A. C. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114485 · Cited by 206
Metadata
- Authors
- Satapathy, M. K., Yen, T.-L., Jan, J.-S., Tang, R.-D., Wang, J.-Y., Taliyan, R., & Yang, C.-H.
- Affiliations
- Taipei Medical University (TW)
- Cathay General Hospital (TW)
- Taipei Medical University Hospital (TW)
- Birla Institute of Technology and Science, Pilani (IN)
- Corresponding author
- Yang, Chih-Hao
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2021-07-31
- Volume
- 13
- Issue
- 8
- Pages
- 1183
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC8402065
- OpenAlex
- W3187770666
- Cited by
- 318
- References
- 268
- Citations by year
- 2026: 64 · 2025: 95 · 2024: 70 · 2023: 55 · 2022: 30 · 2021: 4
- FWCI
- 2.75
- Type
- journal article
- Language
- en
- Update notices
- correction (2026-08-27)
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministry of Science and Technology, Taiwan (MOST-106-2320-B-038-049-MY3, MOST-108-2314-B-038-022)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- solid lipid nanoparticles, blood-brain barrier, brain drug delivery, central nervous system disorders, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, brain tumors, epilepsy, ischemic stroke, nanoparticle synthesis, drug carriers, controlled drug delivery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.